Aller au contenu principal
Fermer

Transgene - Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018
information fournie par Boursorama 12/11/2018 à 07:30

Transgene - Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018


• Primary end-point reached: safety established following single dose and multiple doses administration of TG1050 in chronic hepatitis B patients under antiviral (NUC) therapy
• TG1050 triggers T cell-based immune responses, specific of all 3 encoded HBV antigens, confirming the mechanism of action of the product
• New preclinical data clearly support further investigation of TG1050 in combination with antivirals or immunomodulators

.../...

Valeurs associées

0,6930 EUR Euronext Paris -0,43%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.

106,6 +0,29%
7 827,63 -0,07%
Or
4 156,8 -0,03%
0,77 -3,27%
1,12045 +0,06%
Chargement...